Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease
- PMID: 22097893
- DOI: 10.1111/j.1478-3231.2011.02639.x
Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease
Abstract
Background: Nonalcoholic steatohepatitis (NASH), the most severe form of nonalcoholic fatty liver disease (NAFLD), is associated with inflammation and increased oxidative stress. The neutrophil/lymphocyte ratio (N/L) integrates information on the inflammatory milieu and physiological stress.
Aims: The aim of this study was to determine the utility of N/L ratio to predict the presence of NASH in patients with NAFLD.
Methods: Our cohort consisted of 101 consecutive patients undergoing liver biopsy for clinical suspicion of NAFLD. Patients were divided into two groups: NASH group (n = 50) and not NASH group (n = 51). The stage of fibrosis was measured using a 4-point scale. The total white cell count, neutrophil and lymphocyte counts were recorded, and the N/L ratio was calculated.
Results: The mean age was 49.5 (± 10.8) years and the mean BMI was 31.4 (± 4.9) kg/m(2) . Patients with NASH had a higher N/L ratio compared with patients with not NASH [2.5 (1.9-3.3) and 1.6 (1.2-2.0), respectively, P < 0.001]. The N/L ratio correlated with the NAFLD activity score and its individual components (steatosis, inflammation and ballooning P < 0.001). Patients with advanced fibrosis (F3-4) had an elevated N/L ratio [2.9 (2.0-3.9)] compared with patients with fibrosis stage 1-2 [1.8 (1.2-2.2)], P < 0.001. For each one-unit increase in N/L ratio, the likelihood of having NASH increased by 70% and the likelihood of having fibrosis increased by 50%.
Conclusion: The N/L ratio is higher in patients with NASH and advanced fibrosis. This ratio can be used as a novel noninvasive marker to predict advanced disease.
© 2011 John Wiley & Sons A/S.
Comment in
-
Neutrophil to lymphocyte ratio: a hopeful marker predicting the disease severity in patients with nonalcoholic fatty liver disease.Liver Int. 2012 Aug;32(7):1188; author reply 1189-90. doi: 10.1111/j.1478-3231.2012.02769.x. Epub 2012 Feb 19. Liver Int. 2012. PMID: 22340732 No abstract available.
-
Noninvasive assessment of the effect of treatment in nonalcoholic fatty liver disease: neutrophil to lymphocyte ratio.Liver Int. 2012 Aug;32(7):1189; author reply 1189-90. doi: 10.1111/j.1478-3231.2012.02776.x. Epub 2012 Mar 8. Liver Int. 2012. PMID: 22405038 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous